Astria Clears IND. On pace for YE2022 Data
Insights - Astria (ATXS) announced the FDA clearance of their IND application for STAR-0215 for hereditary angioedema (HAE). A Phase 1a trial of STAR-0215 in healthy volunteers … Continue Reading
PremiumAuthor Archives: D Mero
MDNA11 Continues Reporting Positive Updates, Although No Response Yet
Insights - A story that is developing which could impact the whole bio industry is a healthcare bill making noise in Washington. Congress and the White House are planning … Continue Reading
Premium
Watchlist Heading into 2H 2022
Insights - The biotech market saw the total EV of publicly traded companies continue to rise to start July, up by about 25% from the mid-June lows. … Continue Reading
Premium
9 Meters Long Awaited Data is Disappointingly Vague
Insights - NMTR reported data on short bowel syndrome (SBS), and it was vague, even though the company has delayed this data readout by 6 months. What … Continue Reading
Premium
F-Star Acquired by Sino Subsidiary
Insights - F-Star (FSTX) reported yesterday that it will be acquired by invoX, a U.K.-based subsidiary of Chinese bio Sino Biopharma. Sino Bio is a global top … Continue Reading
PremiumMid-Year Update on Holdings
Research - It has been an eventful week for a few of our holdings. Quick update on each name below. Affimed Update on Manufacturing StrategyWe spoke to … Continue Reading
PremiumBio Seeing Early Life After ASCO 2022 & Big Acquisitions
Insights - The bio sector is seeing some life with improved fundamentals, which could be an early sign of reversal. ASCO in Chicago is wrapping up and … Continue Reading
Premium